Back to Search Start Over

The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.

Authors :
Wang H
Berger KN
Miller EL
Fu W
Broglie L
Goldman FD
Konig H
Lim SJ
Berg AS
Talano JA
Comito MA
Farag SS
Pu JJ
Source :
Therapeutic advances in hematology [Ther Adv Hematol] 2023 May 03; Vol. 14, pp. 20406207231170708. Date of Electronic Publication: 2023 May 03 (Print Publication: 2023).
Publication Year :
2023

Abstract

Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.<br />Objectives: The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.<br />Design: This was a multi-institution retrospective study.<br />Methods: A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.<br />Results: In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, pā€‰=ā€‰0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, pā€‰=ā€‰0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.<br />Conclusion: In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.<br />Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.<br /> (© The Author(s), 2023.)

Details

Language :
English
ISSN :
2040-6207
Volume :
14
Database :
MEDLINE
Journal :
Therapeutic advances in hematology
Publication Type :
Academic Journal
Accession number :
37151808
Full Text :
https://doi.org/10.1177/20406207231170708